Entity Addresses, Address Type [Axis]
Business Contact [Member]
Components of equity [axis]
Issued capital [member]
Other reserves [member]
Warrant reserves [member]
Convertible loan note reserve [member]
Retained earnings [member]
Translation reserve [member]
Classes of property, plant and equipment [axis]
Computer equipment [member]
Classes of intangible assets other than goodwill [axis]
Research and development [member]
Corporate and administration [member]
Defined benefit plans [axis]
Fee and short term employee benefits [member]
Post employment benefits [member]
Categories of related parties [axis]
Directors [member]
Other keymanagement personnel [member]
Directors and other officers [member]
IT equipment [member]
Geographical areas [axis]
UK [member]
US [member]
Issued capital [member]
Warrant reserve [member]
Grant Date [Axis]
March 14, 2023 [member]
October 20, 2023 [member]
November 20, 2023 [member]
March 1, 2024 [member]
March 13, 2024 [member]
October 3, 2024 [member]
January 29 ,2025 [member]
March 28, 2025 [member]
July 10, 2025 [member]
January 2, 2026 [member]
February 10, 2026 [member]
Grant one [member]
Grant two [member]
Grant three [member]
Grant four [member]
Grant five [member]
Range [axis]
Bottom of range [member]
Top of range [member]
Maturity [axis]
Less than 3 months [member]
3 to 12 months [member]
Counterparties [axis]
Tiziana Life Sciences Ltd. [member]
Types of contracts [axis]
Service agreement [member]
Borrowings by name [axis]
Shortterm credit facility [member]
Additional shortterm credit facility [member]
Unsecured loan agreement one [member]
Unsecured loan agreement two [member]
Unsecured loan agreement three [member]
Unsecured loan agreement four [member]
John Brancaccio [member]
Bernard Denoyer [member]
Willy Simon [member]
Gabriele Cerrone [member]
Not later than one year [member]
Legal Entity [Axis]
PKF Littlejohn LLP [member]
Mazars LLP [member]
Cash and cash equivalent [axis]
GBP [member]
European [member]
USD [member]
Products and services [axis]
Phase I Human Clinical Trial [member]
Phase II Human Clinical Trial [member]
Phase III Human Clinical Trial [member]
Entity Addresses [Table]
Entity Addresses [Line Items]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Contact Personnel Name
Contact Personnel Email Address
ICFR Auditor Attestation Flag
Document Financial Statement Error Correction [Flag]
Auditor Firm ID
Auditor Opinion [Text Block]
Auditor Name
Auditor Location
Statement of financial position [abstract]
ASSETS
Current assets:
Cash and cash equivalents
Short Term Investments
Current taxation receivable
Other receivables
Total current assets
Property and Equipment, net
Total non-current assets
Total assets
LIABILITIES AND SHAREHOLDERS’ EQUITY
Liabilities:
Current liabilities:
Trade and other payables
Related party payable
Total current liabilities
Total liabilities
Shareholders’ Equity:
Share premium
Share options reserve
Convertible Loan Note Reserve
Warrants reserve
Foreign currency translation reserve
Retained deficit
Total shareholders’ equity
Total liabilities and shareholders’ equity
Profit or loss [abstract]
Operating expenses:
Research and development
Operating Expenses
Total operating expenses
Other income/(expense):
Finance expense (net)
Loss from operations before income taxes
Income tax
Loss for the year
Other Comprehensive loss:
Exchange differences on translating foreign operations
Comprehensive loss
Basic loss per share attributable to common shareholders
Diluted loss per share attributable to common shareholders
Statement of changes in equity [table]
IfrsStatementLineItems [Line Items]
Balance
Balance, shares
Shares issued for Fundraising, net
Shares issued for Fundraising, net, shares
Expenses settled in shares
Expenses settled in shares, shares
Issuance of shares, related party loan conversion
Issuance of shares, related party loan conversion, shares
Options charge
Options forfeiture
Warrants charge
Total transactions
Total transactions, shares
Loss for the period
Currency translation
Total comprehensive income
Shares issued in lieu of consultancy fees
Shares issued in lieu of consultancy fees, shares
Shares issued in lieu of Bonus
Shares issued in lieu of Bonus, shares
Shares issued in lieu of interest
Shares issued in lieu of interest, shares
Fees on CLN issuance
Fees on CLN issuance, shares
Proceeds from Convertible loan note
CLN settled in Shares
CLN settled in Shares, shares
CLN Interest settled in shares
CLN Interest settled in shares, shares
Balance
Balance, shares
Statement of cash flows [abstract]
CASH FLOWS FROM OPERATING ACTIVITIES:
Loss from operations before income taxes
Adjustments to reconcile net loss to net cash used in operating activities:
Share option charge
Warrant charge
Forfeiture of options
Depreciation of fixed assets
(Gain)/Loss on foreign exchange
Expenses settled in shares
Shares Issued in lieu of consultancy fees
Shares Issued in lieu of bonus
CLN Fees settled in shares
Shares Issued in lieu of interest
Convertible loan interest accrued
Net increase/(decrease) in related party balances
Net (increase)/decrease in operating assets/other receivables
Net increase/(decrease) in trade and other payables
Cash inflow from taxation
Net cash used in operating activities
CASH FLOWS FROM INVESTING ACTIVITIES
Short Term Investments
Acquisition of property, plant and equipment
Net cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from fundraising, net and issuance of ordinary shares
Proceeds from convertible loan note
Net cash provided by financing activities
Net increase/(decrease) in cash and cash equivalents
Cash and cash equivalent, beginning of period
Exchange difference
Cash and cash equivalent, end of period
Non Cash items:
Conversion of related party loan into shares
Conversion of convertible loan note into shares
Convertible loan note interest liability settled by the issuance of shares
Pay vs Performance Disclosure [Table]
Executive Category [Axis]
Individual [Axis]
Adjustment to Compensation [Axis]
Measure [Axis]
Pay vs Performance Disclosure, Table
Company Selected Measure Name
Named Executive Officers, Footnote
Peer Group Issuers, Footnote
Changed Peer Group, Footnote
PEO Total Compensation Amount
PEO Actually Paid Compensation Amount
Adjustment To PEO Compensation, Footnote
Non-PEO NEO Average Total Compensation Amount
Non-PEO NEO Average Compensation Actually Paid Amount
Adjustment to Non-PEO NEO Compensation Footnote
Equity Valuation Assumption Difference, Footnote
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid vs. Net Income
Compensation Actually Paid vs. Company Selected Measure
Total Shareholder Return Vs Peer Group
Compensation Actually Paid vs. Other Measure
Tabular List, Table
Total Shareholder Return Amount
Peer Group Total Shareholder Return Amount
Net Income (Loss)
Company Selected Measure Amount
Other Performance Measure, Amount
Adjustment to Compensation, Amount
PEO Name
Name
Non-GAAP Measure Description
Additional 402(v) Disclosure
Pension Benefits Adjustments, Footnote
Erroneously Awarded Compensation Recovery [Table]
Restatement Determination Date [Axis]
Restatement Determination Date
Aggregate Erroneous Compensation Amount
Erroneous Compensation Analysis
Stock Price or TSR Estimation Method
Outstanding Aggregate Erroneous Compensation Amount
Aggregate Erroneous Compensation Not Yet Determined
Name
Forgone Recovery due to Expense of Enforcement, Amount
Forgone Recovery due to Violation of Home Country Law, Amount
Forgone Recovery due to Disqualification of Tax Benefits, Amount
Forgone Recovery, Explanation of Impracticability
Name
Compensation Amount
Restatement does not require Recovery
Awards Close in Time to MNPI Disclosures [Table]
Award Type [Axis]
Award Timing MNPI Disclosure
Award Timing Method
Award Timing Predetermined
Award Timing MNPI Considered
Award Timing, How MNPI Considered
MNPI Disclosure Timed for Compensation Value
Awards Close in Time to MNPI Disclosures, Table
Name
Underlying Securities
Exercise Price
Fair Value as of Grant Date
Underlying Security Market Price Change
Trading Arrangements, by Individual [Table]
Trading Arrangement [Axis]
Material Terms of Trading Arrangement
Name
Title
Rule 10b5-1 Arrangement Adopted
Non-Rule 10b5-1 Arrangement Adopted
Adoption Date
Rule 10b5-1 Arrangement Terminated
Non-Rule 10b5-1 Arrangement Terminated
Termination Date
Expiration Date
Arrangement Duration
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted
Insider Trading Policies and Procedures Not Adopted
Cybersecurity Risk Management, Strategy, and Governance [Abstract]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]
Cybersecurity Risk Management Processes Integrated [Flag]
Cybersecurity Risk Management Processes Integrated [Text Block]
Cybersecurity Risk Management Third Party Engaged [Flag]
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]
Cybersecurity Risk Board of Directors Oversight [Text Block]
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]
Cybersecurity Risk Role of Management [Text Block]
Cybersecurity Risk Management Positions or Committees Responsible [Flag]
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]
Material Cybersecurity Incident [Abstract]
Material Cybersecurity Incident Nature [Text Block]
Material Cybersecurity Incident Scope [Text Block]
Material Cybersecurity Incident Timing [Text Block]
Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]
Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]
Reporting Entity
Reporting Entity
Notes and other explanatory information [abstract]
ACCOUNTING POLICIES
Critical Accounting Judgements And Key Sources Of Estimation Uncertainty
CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY
OPERATING EXPENSES
Disclosure of entity's operating segments [text block]
SEGMENTAL REPORTING
Employees Including Officers Executive And Non-executive Directors
EMPLOYEES INCLUDING OFFICERS, EXECUTIVE AND NON-EXECUTIVE DIRECTORS
REMUNERATION OF KEY MANAGEMENT PERSONNEL
TAXATION
FINANCE INCOME AND COSTS
PROPERTY, PLANT AND EQUIPMENT
Prepaid Expenses And Other Receivables
PREPAID EXPENSES AND OTHER RECEIVABLES
TRADE AND OTHER PAYABLES
CAPITAL AND RESERVES
SHARE OPTIONS AND WARRANTS
FINANCIAL INSTRUMENTS
RELATED PARTY TRANSACTIONS
BASIC AND DILUTED LOSS PER SHARE
LEASES
AUDITOR’S REMUNERATION
CASH AND CASH EQUIVALENTS AND SHORT TERM INVESTMENTS
Convertible Loan Instruments
CONVERTIBLE LOAN INSTRUMENTS
COMMITMENTS AND CONTINGENCIES
POST BALANCE SHEET EVENTS
Basis of preparation
Basis of measurement
Going Concern
Basis of consolidation
Segment reporting
Taxation
Foreign currency translation
License fees
Research and development
Financial instruments
Cash and cash equivalents
Short-term investments
Impairment
Share capital
Property, plant and equipment
Leases
Share based payments
Warrants
Convertible loan notes
Fair Value Measurement
DISCLOSURE OF ESTIMATED USEFUL LIVES
SCHEDULE OF OPERATING EXPENSES
SCHEDULE OF EMPLOYEES COST AND NUMBER OF EMPLOYEES EXPLANATORY
SCHEDULE OF KEY MANAGEMENT PERSONNEL COMPENSATION
SCHEDULE OF SHARE OPTIONS GRANTED TO DIRECTORS
SCHEDULE OF TAX CREDIT PERIOD
SCHEDULE OF FINANCE INCOME AND COSTS
SCHEDULE OF PROPERTY PLANT AND EQUIPMENT
SCHEDULE OF PROPERTY PLANT AND EQUIPMENT LOCATED IN OPERATING SEGMENT
SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES
SCHEDULE OF TRADE AND OTHER PAYABLES
SCHEDULE OF AUTHORIZED ISSUE UNLIMITED NUMBER OF PAR VALUE SHARES
SCHEDULE OF OPTIONS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE
SCHEDULE OF SHARE OPTIONS OUTSTANDING EXPIRY DATES AND EXERCISE PRICES
SCHEDULE OF SHARE BASED PAYMENT AWARD MODEL INPUTS OPTIONS GRANTED
SCHEDULE OF WARRANTS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE
SUMMARY OF FINANCIAL LIABILITIES BASED ON CONTRACTUAL UNDISCOUNTED PAYMENTS
SUMMARY OF INCOME AND SHARE DATA USED IN THE BASIC AND DILUTED LOSS PER SHARE COMPUTATIONS
SCHEDULE OF CONTRACTUAL MATURITIES OF LEASE LIABILITIES
SCHEDULE OF COMPANY AUDITORS FEES
SCHEDULE OF CASH AND CASH EQUIVALENT
SCHEDULE OF SHORT TERM INVESTMENTS
SCHEDULE OF MILESTONES PAYMENT
Accounting Policies
Accumulated deficit
Net loss
Net cash used in operating activities
Proceeds from sales of intangible assets, classified as investing activities
Disclosure of detailed information about property, plant and equipment [table]
Estimated useful lives
Director fees including bonus (excluding Chairman’s bonus)
Chairman’s bonus
Auditor’s Remuneration (refer to Note 19)
Legal and Professional fees
FX Gains and losses
Depreciation
DisclosureEmployeesIncludingOfficersExecutiveAndNonexecutiveDirectorTable [Table]
Directors’ salaries
Wages and salaries
Social security costs
Recruitment costs
Total employee benefits expense
Total number of employees
Disclosure of defined benefit plans [table]
Total Key Management Personnel
Remuneration Of Key Management Personnel
Post-employment severance payments
Pension contribution
Disclosure of transactions between related parties [table]
Number of options
Current year tax charge
Adjustments in respect of prior periods
Origination and reversal of timing differences
Total tax charge/(credit) for the period
Loss before taxation
Loss charged at standard rate of corporation tax 19%
Tax losses arising in the year not recognized
Expenses not deductible for taxation
Tax increase from effect of capital allowances and depreciation
Difference in tax rates
Research and Development tax credits claimed in respect of previous periods
Consolidation adjustment in relation to foreign exchange movements
Corporation tax rate
Taxation
Tax effect of tax losses
Interest income
Total finance income
Finance Charges
Convertible Loan Note Interest
Interest expense on related party loan
Total finance expenses
Total finance income/(expenses)
Property and equipment, cost, balance
Additions
Disposals
Foreign exchange
Property and equipment, cost, balance
Depreciation, beginning balance
Charge in year
Write Off Disposals
Foreign exchange
Depreciation, ending balance
Net book value
Disclosure of disaggregation of revenue from contracts with customers [table]
Total
Schedule Of Prepaid Expenses And Other Receivables
Other receivables
Related Party receivable
VAT receivable
Prepayments
Prepaid expenses and other receivables
Trade payables
Other payables
Accruals
Bonus accrual
Trade and other payables
Expenses settled in shares, value
Bonus settled in shares
Bonus settled in value
Issue of Shares for fundraising, net, shares
Issue of Shares for fundraising, net, value
Shares in lieu interest
Shares in lieu interest, value
Convertible loan note and interest settled in shares
Convertible loan note and interest settled in shares, value
Capital And Reserves
Dividends paid
Beginning balance, Options outstanding
Beginning balance, Weighted Average Exercise price, outstanding
Options, granted
Weighted Average Exercise price, Granted
Options, forfeited
Weighted Average Exercise price, Forfeited
Options, exercised
Weighted Average Exercise price, Exercised
Ending balance, Options outstanding
Ending balance, Weighted Average Exercise price, outstanding
Options, Exercisable
Ending balance, Weighted Average Exercise price, Exercisable
Disclosure of terms and conditions of share-based payment arrangement [table]
Number of option were exercised
Fair value charge of share option instruments deemed
Share based payment charge
Share based payment charge forfeiture
Weighted average contractual life of options outstanding
Share options granted
Warrant received
Warrants exercisable price
Number of warrants granted or exercised
Fair value of warrants
IfrsStatementTable [Table]
GrantDateAxis [Axis]
Expiration date of outstanding
Exercise Price
Share Options, Outstanding
Disclosure of detailed information about borrowings [table]
Grant date share price
Exercise share price
Vesting periods
Risk free rate
Expected volatility
Option life
Warrants outstanding, beginning balance
Weighted average exercise price, outstanding beginning balance
Warrants granted
Weighted average exercise price, granted
Warrants exercised
Weighted average exercise price, exercised
Warrants outstanding, ending balance
Weighted average exercise price, outstanding ending balance
Warrants exercisable
Weighted average exercise price, exercisable
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [table]
Trade and other payables
Related party payables
Total
DisclosureOfRelatedPartyTransactionsTable [Table]
Service received related party transaction
Amounts payable related party transaction
Settlement of liabilities on behalf of entity by related party transactions
Maximum borrowing capacity amount
Description of borrowing interest rates
Interest rate
Additional interest rate
Borrowings
Accrued interest
Number of shares issued for debt conversion
Debt instruments issued
Noteholder price, per share
Directors fees
(Loss) attributable to equity holders of the company
Weighted average number of ordinary shares in issue
Basic loss per share
Dilutive loss per share
Within one year
ScheduleOfCompanyAuditorsFeesTable [Table]
Fees payable to the company’s auditors for the audit of the parent company and consolidated financial statements
Audit-related assurance services
Total auditor’s remuneration
Cash at bank and in hand
Cash deposits
Convertible loan note conversion
Amount of licensed product or service
Annual license maintenance fee
Annual license maintenance fee, therafter
The disclosure of detailed information about options outstanding and weighted average exercise price explanatory.
Finance charges.
Interest expense on related party loan.
Weighted average number of ordinary shares in issue.
Property and equipment, cost.
IT equipment [member]
Disclosure of accounting policies basis of presentation explanatory
Property plant and equipment depreciation.
Explanation of measurement bases used in preparing financial statements.
Write off disposals.
Effect of foreign exchange depreciation.
Share based payment charge.
Share based payment charge forfeiture.
Grant Date Axis.
March 14, 2023 [member]
October 20, 2023 [member]
November 20, 2023 [member]
March 1, 2024 [member]
March 13, 2024 [member]
January 29 ,2025 [member]
March 28, 2025 [member]
The disclosure of detailed information about contractual maturities of lease liabilities explanatory.
October 3, 2024 [member]
The disclosure of detailed information about company auditors fees explanatory.
July 10, 2025 [member]
January 2, 2026 [member]
February 10, 2026 [member]
Disclosure of Detailed Information About Property Plant And Equipment Located Operating Segment Explanatory [Table Text Block]
Disclosure of Prepaid Expenses And Other Receivables [Text Block]
Expiration date of outstanding.
The disclosure of detailed information about cash and cash equivalents.
Disclosure of detailed information about share based payment award model inputs options granted explanatory.
Cash and cash equivalent [axis]
GBP [member]
European [member]
USD [member]
Disclosure of detailed information about payables and accrued liabilities explanatory.
Disclosure of Detailed Information About Prepaid Expenses and Other Receivables Explanatory [Text Block]
Grant date share options granted.
Vesting period description.
Options life period.
Grant one [member]
Grant two [member]
Issued capital [member]
Grant three [member]
Number of issue of shares for fundraising, net.
Grant four [member]
Expenses settled in shares.
The disclosure of detailed information about short term investments explanatory.
Number of share in lieu interest.
Grant five [member]
Expenses settled in value.
Bonus settled in value.
Number of issue of shares for fundraising, net value.
Number of shares in lieu interest value.
The disclosure of detailed information of convertible loan instruments explanatory.
Number of shares issued for convertible loan note and interest settlement.
Value of shares issued for convertible loan note and interest settlement.
Current taxation receivable
Bonus settled in shares.
Warrants exercisable price per share.
Number of other equity instruments granted or exercised in share based payment arrangement.
Convertible loan note reserve.
Foreign currency translation reserve
Description of accounting policy for license fees explanatory.
Other income expense abstract.
Description of accounting policy for research and development explanatory.
Fair value of warrants.
The tabular disclosure of milestones payments.
The disclosure of detailed information of maturities of financial instruments explanatory.
Amount of Licensed Product or Service.
Phase I Human Clinical Trial [member]
Phase II Human Clinical Trial [member]
Phase III Human Clinical Trial [member]
Warrant reserves [member]
Convertible loan note reserve [member]
Translation reserve [member]
Less than 3 months [member]
3 to 12 months [member]
Tiziana Life Sciences Ltd. [member]
Service agreement [member]
Issuance of shares fundraising net.
Number of shares issued of fundraising net.
Expenses settled in shares.
Expenses settled in shares, shares.
Shares issued value of realted party loan conversion
Shares issued share of realted party loan conversion
Shares issued on options charge
Line of credit facility maximum borrowings capacity.
Shortterm credit facility [member]
Increase decrease through exercise of forfeiture
Increase decrease through exercise of warrants charge
Shares issued on total transactions
Additional borrowings interest rate.
Additional shortterm credit facility [member]
Shares issued on total transactions shares,
Accrued interest on borrowings.
Shares issued on convertible debt conversion, shares.
UK [member]
Shares issued value on lieu of consultancy fees.
Shares issued shares on lieu of consultancy fees.
US [member]
Shares issued value on lieu of bonus.
Shares issued shares on lieu of bonus.
Shares issued value on lieu of interest.
Shares issued shares on lieu of interest.
Shares issued value on fees on CLN issuance.
Description of accounting policy for share capital explanatory.
Shares issued shares on fees on CLN issuance.
Directors fees.
John Brancaccio [member]
Proceeds from convertible loan note.
Bernard Denoyer [member]
Willy Simon [member]
The tabular disclosure for estimated useful lives explanatory.
Gabriele Cerrone [member]
Description of accounting policy for lease explanatory.
Increase (decrease) through CLN settled in shares.
Description of convertible loan notes explanatory.
Disclosure critical accounting judgements and key sources of estimation uncertainty.
Number of shares issued CLN settled in shares.
Unsecured loan agreement one [member]
Increase (decrease) through CLN interest settled in shares.
Effect of charge in year depreciation.
Unsecured loan agreement two [member]
Number of shares issued CLN interest settled in shares.
Unsecured loan agreement three [member]
Unsecured loan agreement four [member]
Adjustments for change in fair value of warrant charge.
Adjustments for change in fair value of forfeiture of options.
Shares issued in lieu of consultancy fees.
Shares issued in lieu of bonus.
Cln fees settled in shares.
Shares issued in lieu of interest.
Convertible loan interest accrued.
Adjustments for increase decrease in related party payables.
Proceeds from fundraising net and issuance of ordinary shares.
Non cash items abstract
Conversion of related party loan into shares
Conversion of convertible loan note into shares.
Convertible loan note interest liability settled by the issuance of shares.
Disclosure of detailed information about operating expenses explanatory.
Director fees.
Chairman bonus.
Foreign exchange loss gain.
Disclosure of employee details explanatory.
Directors salaries.
Research and development [member]
Corporate and administration [member]
Description of borrowing interest rates.
Disclosure of nature of business explanatory
Loss before taxation.
Loss charged at standard rate of corporation tax.
Tax increase from effect of capital allowances and depreciation.
Research and Development tax claim.
Directors [member]
Other keymanagement personnel [member]
PKF Littlejohn LLP [member]
Mazars LLP [member]
Fee and short term employee benefits [member]
Post employment benefits [member]
Disclosure of detailed information about employees explanatory.
Post-employment severance payments.
Directors and other officers [member]
Disclosure of Detailed Information Share Options Granted to Directors Explanatory.
Annual license maintenance fee, therafter.
Annual license maintenance fee.
Warrant received.
Issued capital [member] [Default Label]
Current assets
Non-current assets
Assets
Current liabilities
Liabilities
Equity
Equity and liabilities
Research and development expense
Operating expense
Operating expense excluding cost of sales
Adjustments for income tax expense
Number of shares outstanding
AdjustmentsForChangeInFairValueOfWarrantCharge
AdjustmentsForChangeInFairValueOfForfeitureOfOptions
ExpensesSettledInShares
Cash flows from (used in) operating activities
Purchase of investments other than investments accounted for using equity method
Purchase of property, plant and equipment, classified as investing activities
Cash flows from (used in) investing activities
Cash flows from (used in) financing activities
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes
Forgone Recovery, Individual Name
Outstanding Recovery, Individual Name
Awards Close in Time to MNPI Disclosures, Individual Name
Trading Arrangement, Individual Name
DisclosureOfNatureOfBusinessExplanatory
Description of accounting policy for restricted cash and cash equivalents [text block]
Tax expense (income)
Finance income
FinanceCharges
Interest expense on borrowings
Interest expense on related party loan
Finance costs
PropertyPlantAndEquipmentCost
Disposals, property, plant and equipment
PropertyPlantAndEquipmentDepreciation
WriteOffDisposals
EffectOfForeignExchangeDepreciation
Other receivables [Default Label]
Weighted average exercise price of share options outstanding in share-based payment arrangement
Number of share options forfeited in share-based payment arrangement
Number of share options exercisable in share-based payment arrangement
Weighted average exercise price of share options exercisable in share-based payment arrangement
Number of other equity instruments outstanding in share-based payment arrangement
Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement
Number of other equity instruments exercisable in share-based payment arrangement
Weighted average exercise price of other equity instruments exercisable in share-based payment arrangement
Trade and other payables [Default Label]
Financial liabilities